Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 18/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16460689 | 0.89 | P2RX7 (0.39) | P2RX7OPRL1 | |
| SCHEMBL12701269 | 0.83 | P2RX7 (0.42) | P2RX7OPRL1 | |
| SCHEMBL12701377 | 0.83 | OPRL1 (0.40) | OPRL1RPS6KB1 | |
| SCHEMBL12701211 | 0.83 | RPS6KB1 (0.52) | P2RX7OPRL1RPS6KB1 | |
| SCHEMBL12701432 | 0.82 | OPRL1 (0.39) | P2RX7OPRL1RPS6KB1 | |
| SCHEMBL12724323 | 0.82 | ALDH1A1 (0.51) | P2RX7RPS6KB1 | |
| SCHEMBL12701457 | 0.80 | P2RX7 (0.46) | P2RX7OPRL1 | |
| SCHEMBL1133952 | 0.80 | OPRL1 (0.37) | P2RX7OPRL1RPS6KB1 | |
| SCHEMBL12701395 | 0.80 | ALDH1A1 (0.38) | OPRL1RPS6KB1 | |
| SCHEMBL16460727 | 0.80 | P2RX7 (0.45) | P2RX7OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2931717-B1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-12-07 | — | — | EP | disclosed |
| US-8431704-B2 | Quinoline or isoquinoline substituted P2X7 antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2013-04-30 | — | — | US | disclosed |
| US-8431704-B2 | Quinoline or isoquinoline substituted P2X7 antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2013-04-30 | — | — | US | disclosed |
| EP-2285800-B1 | QUINOLINE OR ISOQUINOLINE SUBSTITUTED P2X7 ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2011-11-16 | — | — | EP | disclosed |
| US-20110092481-A1 | QUINOLINE OR ISOQUINOLINE SUBSTITUTED P2X7 ANTAGONISTS | JANSSEN PHARMACEUTICA NV | 2011-04-21 | — | — | US | disclosed |
| US-20110092481-A1 | QUINOLINE OR ISOQUINOLINE SUBSTITUTED P2X7 ANTAGONISTS | JANSSEN PHARMACEUTICA NV | 2011-04-21 | — | — | US | disclosed |
| EP-2285800-A1 | QUINOLINE OR ISOQUINOLINE SUBSTITUTED P2X7 ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2011-02-23 | — | — | EP | disclosed |
| WO-2009132000-A1 | QUINOLINE OR ISOQUINOLINE SUBSTITUTED P2X7 ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009132000-A1 | QUINOLINE OR ISOQUINOLINE SUBSTITUTED P2X7 ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092481-A1 | QUINOLINE OR ISOQUINOLINE SUBSTITUTED P2X7 ANTAGONISTS | P2RX7, P2RX1, P2RX3 | P2RX7 1/4885OPRL1 83/4885RPS6KB1 1281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.